Han Tun, MD
Hematology & Oncology · Jacksonville, FLNPI 1760471494
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Aurobindo Pharma USA, Inc. accounts for 83.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $6,327 and has fallen 97.2% since, to $175 in 2023.
Across 12 payments — averaging $1113.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurobindo Pharma USA, Inc.$11K
- ADC Therapeutics America, Inc.$2K
- Abbott$175
Across 39 payments — averaging $10,609 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acrotech Biopharma Inc.$279K
- Eli Lilly$74K
- Epizyme, Inc.$39K
- TG Therapeutics, Inc.$17K
- Bristol Myers Squibb$3K
- Bayer$950
What the payments were for
- Consulting fees$6,30047%
- Speaking & faculty fees$5,50041%
- Travel & lodging$1,0588%
- Food & beverage$4984%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurobindo Pharma USA, Inc. | 10 | $11,186 |
| ADC Therapeutics America, Inc. | 1 | $2,000 |
| Abbott | 1 | $175 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zevalin$11,115
- CARDIOMEMS$175
How this compares
$13,361 in reported general payments places this provider in the 65th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 21 | $332,385 |
| BrukinsaZanubrutinib | 24 | $325,313 |
| RevlimidLenalidomide | 14 | $258,531 |
| Acyclovir | 21 | $238 |
| Gabapentin | 20 | $164 |
| Pantoprazole Sodium | 14 | $89 |
| Prednisone | 28 | $69 |
| Prochlorperazine Maleate | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.